Please login to the form below

Not currently logged in
Email:
Password:

Novo's world-leading insulin plant to get even bigger

Danish firm invests €54m in Kalundborg expansion
Novo Nordisk Kalundborg

Novo Nordisk's product plant in Kalundborg, Denmark - already the largest insulin manufacturing site in the world - is set for further expansion.

The Danish diabetes specialist is investing DKK 400m (around €54m) to enlarge the site on the northwestern coast of Zealand by 500m2.

Michael Hallgren, senior vice president and head of production in Kalundborg, said: "The expansion of our production plant highlights our ambition to continue strengthening our presence in Kalundborg.

“The new facilities will give us greater flexibility and enable the installation of equipment that will enhance efficiency and increase the long-term production capacity of the plant.”

The site, which employs some 3,400 people, is a cornerstone of Novo's global production and produces 50% of the world's insulin as well as a range of biopharmaceutical products.

The investment in the plant comes just over a month after Novo won unanimous backing from FDA advisors for the approval of IDeglira, its once-daily, fixed-dose combination Tresiba (insulin degludec) and Victoza (liraglutide).

A groundbreaking for the Kalundborg plant's extension will take place today and work is expected to be completed by the end of 2018.

Article by
Dominic Tyer

4th July 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

mHealth: The revolution will not be digital
...
Medical information in precision medicine
Global Medical Information Leader James Oughton reveals the top trends in medical information and precision medicine....
Australian Flu and the dilemma of naming diseases
...

Infographics